Qing Dong - San Diego CA, US Xianchang Gong - San Diego CA, US Stephen W. Kaldor - Del Mar CA, US Toufike Kanouni - San Diego CA, US Nicholas Scorah - San Diego CA, US Michael B. Wallace - San Diego CA, US Feng Zhou - Escondido CA, US
Compounds of the following formula are provided for use with MEK:wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
Qing Dong - San Diego CA, US Xianchang Gong - San Diego CA, US Stephen W. Kaldor - Del Mar CA, US Toufike Kanouni - San Diego CA, US Nicholas Scorah - San Diego CA, US Michael B. Wallace - San Diego CA, US Feng Zhou - Escondido CA, US
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED - Osaka-shi, Osaka
Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
The invention relates to PI3K/mTOR inhibiting compounds consisting of the formula:wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
N-(Cyano-Substituted Benzyl Or Pyridinylmethyl)-3-Hydroxypicolinamide Derivatives
Benjamin Jones - San Diego CA, US Andre Kiryanov - San Diego CA, US Jon Kuehler - San Diego CA, US Marion Lanier - San Diego CA, US Sean Murphy - San Diego CA, US Feng Zhou - San Diego CA, US - Osaka, JP
International Classification:
C07D 213/81
Abstract:
Disclosed are compounds of Formula 1,and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, Xand Xare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with PHD.